Pancreatic cancer vaccine shows promise

Vaccine targeting pancreatic cancer shows promise in new study of clinical trial
A clinical trial from Memorial Sloan Kettering Cancer Center looked at the effects of a targeted mRNA vaccine on early-stage pancreatic cancer patients.
Can mRNA vaccines help in the fight against pancreatic cancer?
There is new hope in the fight against pancreatic cancer after early trials showed that personalized mRNA vaccines can target and reduce malignant tumors. NBC News medical contributor Dr. Kavita Patel reports on the vaccine’s success against pancreatic cancer,
Vaccine shows promise for treating pancreatic cancer, study shows
A personalized mRNA vaccine appeared to reduce the chances of pancreatic cancer returning after surgery, according to a study published in the journal Nature.
Experimental vaccine for common cancer shows potential in clinical trial
A Memorial Sloan Kettering phase 1 clinical trial revealed an immune response in some pancreatic cancer patients. Study co-author Dr. Vinod Balachandran talks about the impact on future cancer care.
A Vaccine For Pancreatic Cancer Continues To Show Promise
In a small trial, nearly half of pancreatic cancer patients who received an mRNA vaccine for the disease had no relapse three years later.
Could a personalized vaccine help fight pancreatic cancer?
"GMA" examines a preliminary study where a personalized mRNA vaccine showed promise in reducing the risk of pancreatic cancer returning after surgery.
AOL3d
Personal vaccine may reduce risk of pancreatic cancer returning after surgery, small study finds
A personalized mRNA vaccine may reduce the risks of pancreatic cancer returning after surgery, according to a preliminary study published Wednesday in the journal Nature. Pancreatic cancer ...
Pancreatic cancer vaccine shows promise, according to study
In trials, a vaccine for pancreatic cancer developed by Sloan-Ketterin and BioNTech showed promise, but researchers say it is ...
Vaccine Shows Promise for Pancreatic Cancer, Study Finds
In a small trial, 8 of 16 patients responded well to the mRNA vaccine The vaccine is personalized, based on each patient’s ...